

# Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management

Satish S. C. Rao, MD, PhD<sup>1</sup> and Jigar Bhagatwala, MBBS, MPH<sup>1</sup>

**Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its prevalence is unknown because SIBO requires diagnostic testing. Although abdominal bloating, gas, distension, and diarrhea are common symptoms, they do not predict positive diagnosis. Predisposing factors include proton-pump inhibitors, opioids, gastric bypass, colectomy, and dysmotility. Small bowel aspirate/culture with growth of  $10^3$ – $10^5$  cfu/mL is generally accepted as the “best diagnostic method,” but it is invasive. Glucose or lactulose breath testing is noninvasive but an indirect method that requires further standardization and validation for SIBO. Treatment, usually with antibiotics, aims to provide symptom relief through eradication of bacteria in the small intestine. Limited numbers of controlled studies have shown systemic antibiotics (norfloxacin and metronidazole) to be efficacious. However, 15 studies have shown rifaximin, a nonsystemic antibiotic, to be effective against SIBO and well tolerated. Through improved awareness and scientific rigor, the SIBO landscape is poised for transformation.**

*Clinical and Translational Gastroenterology* 2019;10:e00078. <https://doi.org/10.14309/ctg.0000000000000078>

## INTRODUCTION

The adult gastrointestinal (GI) tract has the largest microbial population in the human body (1); the predominant site is the colon, containing 38 trillion bacteria (2). Culture-independent methods, such as next-generation sequencing, show low concentration of distinct bacterial populations in the duodenum of healthy individuals, in contrast with bacterial populations that inhabit the mouth (3). Bacterial concentrations increase progressively along the small intestine (4,5).

Small intestinal bacterial overgrowth (SIBO) is characterized by the presence of an abnormal amount of bacteria in the small intestine together with a constellation of GI symptoms. The purpose of this article is to provide an up-to-date review of SIBO, including symptom patterns, predisposing risk factors, prevalence, specialized diagnostic testing, and potential therapeutic interventions, and to describe gaps in our knowledge and unmet needs.

## METHODS

A PubMed search was performed on June 8, 2018, to identify English-language publications of clinical trials pertaining to SIBO in adults since 1985 using the search terms “small bowel bacterial overgrowth,” “small intestinal bacterial overgrowth,” “SIBO,” “epidemiology,” “diagnosis,” “treatment,” “antibiotic (e.g., ciprofloxacin, cotrimoxazole, and metronidazole),” “rifaximin,” or “probiotic.” Clinical studies of rifaximin ( $n = 15$ ), systemic antibiotics ( $n = 6$ ), and probiotics ( $n = 3$ ) in SIBO were included, whereas studies of combination therapies, for example, rifaximin with another antibiotic and/or other combination of systemic antibiotics or probiotics, were excluded from this review. A total of 23 references on predisposing factors and 4 on diagnostic

testing for SIBO were included. Although we recognize that SIBO occurs in a wide spectrum of diseases discussed below, most literature on this topic has focused on patients presenting with either unexplained symptoms or symptoms of irritable bowel syndrome (IBS). Our review primarily focuses on these patients, as they are most commonly encountered in gastroenterology clinics, but other conditions are appropriately referenced wherever necessary.

## CLINICAL FEATURES, PREVALENCE, AND PATHOETIOLOGY

Symptoms of SIBO are nonspecific and include abdominal pain, belching, bloating, diarrhea, distension, flatulence, and indigestion that overlap and vary in frequency, duration, and severity. Typically, over two-thirds of patients report the aforementioned symptoms (6,7). Diagnosis of SIBO is challenging, as illustrated by 1 study in which mean total symptom scores were similar regardless of whether patients tested positive or negative with duodenal aspirate and breath testing ( $P = 0.9$ ) (6). Because a SIBO diagnosis requires specialized testing (e.g., microbial culture and breath testing), and owing to variability in patient populations and methods used to establish a diagnosis across studies (8), prevalence has been difficult to estimate. However, SIBO appears to be more prevalent in women and in older individuals (9).

Several factors are associated with or predispose patients to SIBO, including small intestinal dysmotility (10). A study using duodenal aspirate/culture demonstrated that patients with small intestinal dysmotility were at increased risk of SIBO ( $>10^3$  colony-forming units [cfu]/mL threshold, odds ratio [OR], 3.6;  $P = 0.0003$ ;  $>10^5$  cfu/mL threshold, OR, 2.7;  $P = 0.005$ ) (7).

<sup>1</sup>Augusta University, Augusta, Georgia, USA. **Correspondence:** Satish S. C. Rao, MD, PhD. E-mail: [srao@augusta.edu](mailto:srao@augusta.edu).

Received March 18, 2019; accepted August 5, 2019; published online October 3, 2019

© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

Indeed, a significantly greater percentage of patients with IBS and SIBO were considered to have dysmotility vs patients with IBS without SIBO (86% vs 39%, respectively;  $P = 0.02$ ) (11). Besides IBS, conditions that have been associated with SIBO include inflammatory bowel disease, dyspepsia, rosacea, restless legs syndrome, small bowel diverticula, pancreatitis, hypothyroidism, Parkinson's disease, diabetes, coronary artery disease, and abdominal surgery (e.g., hysterectomy, gastrectomy, cholecystectomy, and colectomy). However, the prevalence of SIBO in patients with these associated conditions is highly variable (range, 4%–79%) (11–16). In a 2018 case-control study, a significantly greater percentage of patients who underwent colectomy had SIBO compared with patients with long-standing GI complaints without colectomy (62% vs 32%, respectively;  $P = 0.0005$ ) (17).

Some studies have suggested an association between SIBO and use of proton-pump inhibitors (PPIs) (7,18,19); however, others have not (9,20). PPIs may predispose patients to bacterial overgrowth by decreasing gastric acid (21). An initial study reported that 56% of 25 patients with peptic ulcers who received omeprazole had SIBO compared with none of 15 controls referred for diagnostic endoscopy ( $P = 0.0003$ ). Subsequent studies have confirmed the association of SIBO with PPIs (18,19), including a retrospective study ( $n = 1,263$  duodenal aspirates), showing that PPI use was significantly greater in patients with positive duodenal culture results compared with negative culture results (52.6% vs 30.2%, respectively;  $P < 0.0001$ ) (18). Results of a 2017 meta-analysis of 19 studies ( $N = 7,055$ ) confirmed a higher risk of SIBO with PPI use (OR, 1.7; 95% confidence interval [CI], 1.2–2.4) (22). A recent study demonstrated that probiotic bacteria may colonize the small bowel and predispose patients to SIBO and brain foginess (23). Thus, numerous factors predispose an individual to the development of SIBO (Table 1) (7,9,11–19,23–34). Interestingly, up to 13% of healthy individuals have also tested positive for SIBO, based on the results of breath testing or small bowel aspirate and culture (26,35–41).

## DIAGNOSIS OF SIBO

Small bowel culture is widely accepted as the “best diagnostic method” for establishing a diagnosis of SIBO (9); a threshold of  $\geq 10^3$  cfu/mL is recommended as a positive test result for SIBO, especially when performing duodenal aspirate and culture, because of very low bacterial counts in this more acidic environment (6–8). However, some investigators have suggested a higher threshold of  $\geq 10^5$  cfu/mL based on traditional microbiological standards for bacterial infection and for jejunal culture (11–13,42,43). In culture-based diagnostic testing, aseptic technique is critical to minimize cross-contamination from outside the duodenum (6), and standardized methods are needed (8). To this end, aspiration of duodenal juice by endoscopic suction and collection in a container may be fraught with contamination (18). One study described the use of a double-lumen catheter for collection of small bowel aspirate to prevent oropharyngeal cross-contamination of the sample (12), but this device is not commercially available. For more than 2 decades, we have successfully used a 6F Liguory catheter (COOK Medical, Bloomington, IN) with multiple side holes at its tip (Figure 1) for collection of small bowel aspirate. The catheter assembly and aspiration kit is first prepared by wearing sterile gloves before the procedure (Figure 1). Next, a sterilized upper endoscope, kept in a sterile wrap and flushed with sterile water

**Table 1. Predisposing factors for SIBO**

Category	Factor
Demographics	Female sex (9)
	Age (9)
Medication use	PPIs (7,18,19)
	Opioids (23)
GI conditions	Dyspepsia (24)
	IBD (9,25)
	IBS (11–14)
	Intestinal dysmotility (7)
	Small bowel diverticula (9)
Other conditions	Systemic sclerosis (33)
	Abdominal surgery (i.e., hysterectomy, gastrectomy, cholecystectomy, colectomy, and Roux-en-Y gastric bypass) (17,26,34)
	Coronary artery disease (16)
	Diabetes (27)
	Hypothyroidism (28)
	Pancreatitis (9,29)
	Parkinson's disease (30)
	Restless legs syndrome (31)
	Rosacea (32)
	GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; PPI, proton-pump inhibitor; SIBO, small intestinal bacterial overgrowth.

before intubation, is passed into the second/third portion of the duodenum using minimal air insufflation. Thereafter, the staff change to another set of sterile gloves to prevent contamination during specimen collection. The endoscopist then passes the Liguory catheter through the biopsy channel of the scope, using the short overtube to prevent biopsy valve contamination. The technician is usually seated for gravity-assisted suction and flow and gently aspirates fluid by repeated suction using a 5-mL sterile syringe connected to a 3-way stopcock. If the lumen is dry, the liver may be gently massaged to facilitate the flow of bile into the duodenum. Typically, within approximately 2–5 minutes, 3 mL of bile-stained duodenal juice is successfully aspirated (Figure 1) (17). The syringe is capped with a sterile cap, and the specimen is placed in a biohazard bag and immediately sent to the microbiology laboratory for aerobic and anaerobic cultures (6,7,44).

Care is taken not to aspirate oral secretions or stomach juices before securing the scope in the duodenum and passing the catheter. In the microbiology laboratory, after vortexing the sample, the following agar plates are inoculated using a 0.001 calibrated loop: blood, chocolate, MacConkey, Columbia nalidixic acid with blood, anaerobic blood, phenyl ethyl alcohol, Remel Anaerobic LPV Blood (Thermo Fisher Scientific, Waltham, MA), which contains paromomycin and vancomycin, inhibitory mold, and mycobiotic. Agar plates are then struck for the colony count. The blood and chocolate agars are held at 37 °C in carbon dioxide for 5 days. MacConkey and Columbia nalidixic



**Figure 1.** Description of the procedure for duodenal aspiration, specimen collection, and handling: The technician flushes the scope with sterile water and prepares a sterile field. A Liguory catheter with a stopcock is assembled (a). The scope is passed into the second/third portion of the duodenum with minimal air insufflation and suctioning. The endoscopist and the technician wear sterile gloves and advance the Liguory catheter through the biopsy channel. The technician performs gravity-assisted aspiration by holding the syringe at a height lower than the patient to aid fluid flow. Using gentle suction, ~3 mL of duodenal fluid is collected and immediately transferred to the microbiology laboratory (b).

acid plates are held in oxygen for 48 hours before being discarded. Anaerobic media are incubated under anaerobic conditions for 5 days. Any bacterial growth  $\geq 1,000$  cfu/mL is identified and reported out using colony count numeration. The organisms (i.e., *Neisseria* sp, Gram-positive bacilli resembling diphtheroids/coryneforms, *Lactobacillus* species, *Streptococcus* viridans group, *Staphylococcus* coagulase negative, and *Rothia* sp.) are identified based on gram stain, colonial morphology, or spot tests. Whenever appropriate, antibiotic susceptibility panels are performed and reported (17).

The limitations of small bowel culture include its invasive nature, cost, potential inability to detect bacterial strains that are difficult to grow under standard culture conditions, detection of proximal SIBO only, and potential for sample contamination (6,8).

Breath testing is a safe and noninvasive diagnostic method for SIBO. However, there is currently no standard methodology for breath testing (8). During a breath test, patients ingest a carbohydrate substrate that is metabolized when exposed to GI microbes, leading to the production of hydrogen and methane. Some of these gases are absorbed from the GI tract into the blood stream and finally exhaled through the lungs, and therefore, analysis of breath samples after carbohydrate ingestion provides an indirect measure of detecting SIBO (45). Glucose and lactulose are commonly used as breath test substrates for detecting SIBO (Table 2) (6,8,46).

In 2017, the North American consensus regarding breath testing (8) provided updates to previously published statements by expert groups from Germany and Italy in 2005 and 2009, respectively (47,48). The consensus recommends that patients avoid treatment with antibiotics for 4 weeks and promotility agents and laxatives for at least 1 week before breath testing (8). Furthermore, a strict bland diet, including avoidance of fermentable foods (e.g., complex carbohydrates), is recommended for the day before administration of the breath test. Patients should also fast 8–12 hours before the breath test, avoid smoking the day of the breath test, and minimize physical exertion during the breath test (8).

The North American consensus for breath testing recommends administering 75 g of glucose or 10 g of lactulose, taken with or followed by 1 cup of water; breath testing should measure hydrogen, methane, and carbon dioxide (see Table 2 for test characteristics) (8). An increase in hydrogen concentrations of  $\geq 20$  ppm from baseline within 90 minutes (8) (Figure 2a,b) (49) and an increase from baseline in methane concentrations of  $\geq 10$  ppm within 2 hours are considered diagnostic of SIBO (Figure 2a,c) (8,49). When using lactulose as a substrate, an initial duodenal peak from bacterial overgrowth in the small intestine followed by a second hydrogen peak from colonic bacterial fermentation has been observed (50), although both hydrogen peaks are not required for the diagnosis of SIBO (8). In addition, the first peak must occur within 90 minutes of substrate administration

**Table 2. Diagnostic tests for SIBO**


Diagnostic test	Substrate and characteristic	Testing protocol	Test interpretation <sup>a</sup>	Diagnostic performance	Limitations
Breath test					
Glucose <sup>8,46</sup>	Monosaccharide <ul style="list-style-type: none"> <li>Absorbed in the proximal small intestine</li> </ul>	75 g of glucose in 250 mL of water Breath samples are collected at baseline and every 15 min for 90–120 min and measured for hydrogen and methane	Rise in hydrogen $\geq 20$ ppm from baseline Or Rise in methane $\geq 10$ ppm from baseline Or Rise in hydrogen and methane combined $\geq 15$ ppm from baseline	Sensitivity: 20%–93% Specificity: 30%–86%	A negative test excludes proximal SIBO, but not distal SIBO Not suitable for patients with diabetes
Lactulose <sup>8,46</sup>	Disaccharide <ul style="list-style-type: none"> <li>Nonabsorbable</li> <li>Reaches the colon</li> <li>Used to measure orocecal transit in some cases</li> </ul>	10 g of lactulose Breath samples are collected at baseline and every 15 min for 180–240 min for hydrogen	Interpretation of the test results requires reliable differentiation of the colonic peak from the small intestine peak <sup>b</sup> Positive test: increase from baseline $\geq 20$ ppm H <sub>2</sub> by 90 min	Sensitivity: 31%–68% Specificity: 44%–100%	May accelerate gut transit, giving the false-negative results May cause bloating Interpretation difficult if only 1 peak in hydrogen concentration
Fructose <sup>8</sup>	Monosaccharide <ul style="list-style-type: none"> <li>Absorbed in the proximal small intestine</li> <li>Suitable for patients with diabetes</li> </ul>	25 g of fructose in 250 mL of water Breath samples are collected at baseline and every 15 min for 180 min and measured for hydrogen and methane	Rise in hydrogen $\geq 20$ ppm above baseline Or Rise in methane $\geq 10$ ppm above baseline Or Rise in hydrogen and methane combined $\geq 15$ ppm from baseline	Sensitivity: 25%–71% Specificity: 42%–92%	Observation based on the single study Cannot differentiate between SIBO and fructose intolerance in patients with diabetes
Small bowel aspirates/ culture					
Duodenal <sup>6,8</sup>	Upper endoscopy performed to obtain samples from the third or fourth portion of the duodenum	3–5 mL of duodenal liquid aspirated using an aseptic technique (e.g., sterile gloves) Samples sent to the laboratory immediately after collection	Positive test: $\geq 10^3$ cfu/mL 65.5% agreement between GBT and duodenal aspirate/culture	Currently, the most widely accepted best diagnostic method for SIBO	Testing is invasive, time intensive, and expensive
Jejunal <sup>8</sup>	Upper endoscopy performed to obtain samples from the proximal jejunum	$\geq 2$ mL of jejunal liquid aspirated Samples sent to the laboratory in sterile fashion immediately	Positive test: $\geq 10^3$ cfu/mL	Currently, the most widely accepted best diagnostic method for SIBO	Testing is invasive, time intensive, and expensive

<sup>a</sup>Glucose dose of 50 g with rise in hydrogen  $>12$  ppm from baseline is also considered positive.

<sup>b</sup>North American consensus no longer considers 2 peaks on a lactulose breath test a requirement for establishing a diagnosis of SIBO (8).

The table created with data from Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. *Am J Gastroenterol* 2017;112:775–84 (8); Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: Duodenal aspiration vs glucose breath test. *Neurogastroenterol Motil* 2015;27:481–9 (6); and Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: An evidence-based review of indications and pitfalls in interpretation. *Am J Gastroenterol* 2002;97:1113–26 (46).

GBT, glucose breath test; SIBO, small intestinal bacterial overgrowth.



**Figure 2.** Typical example of breath test results: Shown are a negative breath test result (a), a positive hydrogen breath test showing hydrogen concentration rising >20 ppm from baseline (b), and a positive breath test showing methane concentration rising >10 ppm from baseline (c). Red lines show hydrogen concentrations, and black lines show methane concentrations. Duodenal aspirates and culture results are shown in the text inset of (b).

for the test to be considered positive (Table 2) (8). Although lactulose breath testing has higher sensitivity than glucose, scintigraphic studies have shown that the rise in breath hydrogen coincides with the arrival of lactulose in the cecum, raising concerns for a false-positive result; by contrast, the glucose breath test (GBT) has good specificity but low sensitivity, as it detects only proximal SIBO because glucose is completely absorbed in the

proximal jejunum (Table 2) (8,46). A study from Lin and Massey (51) demonstrated that rapid transit of glucose into the cecum may provide a false-positive breath test within 90 minutes, possibly because of colonic fermentation, based on GBT combined with nuclear scintigraphy. Although possible, the likelihood of glucose reaching the cecum is low, as glucose is usually completely absorbed in the proximal small bowel. On the other hand,

lactulose invariably will reach the cecum, as it is a nonabsorbable disaccharide (52). Arguably, scintigraphy is an imperfect test to localize the cecum. Small bowel loops or diverticula overlying the cecal region could be erroneously reported as a tracer filling this area. Also, the head of the meal may have reached the cecum, but the bulk of the meal could remain in the small intestine undergoing fermentation from SIBO, and both sources of fermentation could produce a rise in breath hydrogen or methane. Consequently, better substrates, better localization methods, and further validation are needed to settle this dilemma.

Microbial culture and breath testing used to diagnose SIBO do not always produce similar findings (6,12). In 1 study, duodenal aspirate culture (i.e.,  $\geq 10^3$  cfu/mL) and GBT (i.e., increase from baseline of both hydrogen and methane  $\geq 20$  ppm, of hydrogen  $\geq 20$  ppm, or of methane  $\geq 15$  ppm) agreed on the diagnosis of SIBO in 65.5% of 139 patients with GI-related symptoms (i.e., abdominal discomfort, gas, bloating, and diarrhea) considered related to SIBO (6). Another study found that although 39% of 18 patients were positive for SIBO with GBT, these results correlated poorly with jejunal culture results, suggesting that further validation is required. Therefore, 1 testing method may not definitively diagnose SIBO, and additional testing may be necessary when SIBO is suspected (6).

The North American consensus recommended a cutoff of  $\geq 10^3$  cfu/mL when using culture methods for the diagnosis of SIBO (8). Although additional validation studies are warranted to standardize breath testing including optimal cutoff thresholds (8), new approaches of breath testing have been investigated. A 2017 study reported the results of administering glucose through endoscope rather than oral ingestion in patients with a negative oral GBT (53). The results showed an increased yield for the diagnosis of SIBO, implying that endoscopic administration of glucose may facilitate detection of distal SIBO. This requires further validation with combined scintigraphy to reassure that the rise is not from colonic fermentation. A novel, orally ingested capsule technology that can measure *in vivo* hydrogen and carbon dioxide after ingestion of a carbohydrate meal is currently under development and may provide a better alternative to current breath hydrogen measurement techniques (54). Also, another novel oral diagnostic capsule, a smart capsule bacterial detection system, has been developed and tested *ex vivo* (55). This system can detect bacteria and, in a noninvasive manner, provides bacterial concentration; however, further clinical trials and validation are needed to assess the use of the smart capsule bacterial detection system for SIBO diagnosis (55).

## TREATMENT OF SIBO

The goal of treatment for patients with SIBO is symptom relief by eradicating overgrowth of bacteria. This is typically achieved by treatment with antibiotics. However, some patients may remain symptomatic despite treatment, suggesting that other underlying conditions (e.g., dysmotility and PPI use) may potentially be the cause of symptoms and/or the bacteria may be antibiotic resistant (56). Hence, effective treatment includes eradication of bacteria, treatment of predisposing conditions, and prevention of SIBO. To date, no drugs have received regulatory approval in the United States or Europe specifically for the treatment of SIBO. However, the following treatments have been studied in patients with SIBO.

Rifaximin, a nonsystemic antibiotic, is currently the most studied agent for patients with SIBO, with numerous studies demonstrating its efficacy (e.g., eradication of SIBO), although the

dose and duration of treatment, SIBO diagnostic methods and definitions, and patient populations vary among studies (Table 3) (15,18,25,28,30,57–66). A systematic review and meta-analysis of rifaximin (dose range: 600–1,600 mg/d; duration of treatment: 5–28 days) reported that SIBO was eradicated (determined by glucose or lactulose breath testing) in 70.8% of patients (26 studies; 95% CI, 61.4–78.2) (67). Adverse events (AEs) were uncommon and occurred in 4.6% of 815 patients from 17 studies reporting safety (67). In the meta-analysis (67), patients discontinued rifaximin treatment because of an AE (5% of 120 patients) in only 1 study (68). *Clostridium difficile* infection was reported in 1 patient receiving rifaximin 1,200 mg/d for 4 weeks; however, detailed information was lacking (59,67).

## Systemic antibiotics

Studies of systemic antibiotics (e.g., ciprofloxacin, norfloxacin, and metronidazole) also reported eradication of SIBO as determined by either the breath test or bacterial culture (Table 4) (43,69–73). However, the sample sizes are small, and the methodologies used and populations evaluated differ across studies. A meta-analysis of 10 prospective clinical studies of nonsystemic antibiotics in patients with SIBO reported higher rates for breath test normalization with an antibiotic vs placebo (51.1% vs 9.8%, respectively; effectiveness ratio, 2.6; 95% CI, 1.3–5.0;  $P = 0.03$ ) (56). Normalization of the breath test occurred in 49.5% of the pooled population ( $n = 325$ ) treated with a nonsystemic antibiotic, rifaximin. The response rate varied widely (21.7%–85.0%), possibly because of rifaximin dosing and the timing of the breath test. Normalization of the breath test with metronidazole, a systemic agent ( $n = 86$ ), was observed in 51.2% of patients (56). Finally, 70% of patients with SIBO and brain foginess who received different antibiotics reported significant improvement of SIBO symptoms ( $P = 0.005$ ), and 85% achieved complete resolution of brain foginess ( $P = 0.05$ ) (23).

## Probiotics

Probiotics are believed to have beneficial effects on the gut microbiota. However, few clinical studies have examined this option (Table 4) (74–76); furthermore, these studies lack consistency not only in the formulations used but also in the duration of treatment, populations assessed, and methods of diagnosing SIBO (74,75). In a safety study, probiotics were not associated with AEs (76). More recently, a 2017 meta-analysis of 18 studies reported that probiotics were associated with significantly increased clearance of SIBO compared with nonprobiotic therapy (6 studies; relative risk, 1.6; 95% CI, 1.2–2.2), although probiotics were not found to be efficacious for the prevention of SIBO (77). Furthermore, probiotics may inadvertently colonize the small bowel, causing both SIBO and D-lactic acidosis, as well as brain foginess (23). Some experts consider these findings to be controversial (78).

## Nonpharmacologic and dietary therapies

Several nonpharmacologic treatments have been proposed because of the cost and potential adverse effects of antibiotics and probiotics. One such approach is an elemental diet, which contains predigested micronutrients that are mostly absorbed within the proximal small bowel, thus limiting the delivery of nutrients to bacteria in the distal portion of the small intestine (79). In a retrospective review, 124 patients with SIBO received an elemental diet for 14 days; patients without normalization of breath

**Table 3. Summary of clinical studies of rifaximin**

Study and design	Location and population	Method used to diagnose SIBO	Pts with SIBO	Treatment	Efficacy
Bae et al. <sup>57</sup> Retrospective study	South Korea Pts with IBS-D or IBS-M (N = 192)	LBT (10 g of lactulose/15 mL of water; BT result at baseline $\geq 20$ ppm, or an increase from baseline $>20$ ppm H <sub>2</sub> or CH <sub>4</sub> $\leq 90$ min)	100%	Rifaximin 1,200 mg/d (N = 192) for 4 wk (initial tx); LBT repeated every 4 wk until normalization with maintenance tx (max, 12 wk)	102 pts had normalized LBT results after receiving rifaximin for 4 wk (n = 36), 8 wk (n = 43), or 12 wk (n = 23) Rifaximin significantly improved symptom scores in pts receiving rifaximin for 4, 8, and 12 wk (P < 0.05, for all comparisons)
Franco et al. <sup>18</sup> Retrospective review	United States Pts undergoing upper endoscopy (N = 1,263) for diarrhea (n = 480), gas-related symptoms (n = 419), diffuse/upper abdominal pain (n = 397), dyspepsia/GERD (n = 199), and/or nausea/vomiting (n = 174)	Bacterial culture ( $>10^5$ cfu/mL)	30.4%	Antibiotic use in pts with positive culture results: Rifaximin: 73.4% Ciprofloxacin: 6.9% Metronidazole: 5% (dosage not provided)	Overall, significant symptom improvement in pts receiving antibiotics (53.1%) vs no antibiotics (24.6%; P < 0.0001) In pts with a positive culture result, clinical improvement in pts receiving antibiotics (53%) vs no antibiotics (46.5%; P = NS)
Greco et al. <sup>25</sup> Prospective study	Italy Pts with CD (N = 68)	GBT (75 g of glucose/150 mL of water; BT result indicating an increase from baseline $\geq 12$ ppm H <sub>2</sub> and/or CH <sub>4</sub> $\leq 180$ min, in $\geq 3$ samples taken every 30 min)	26.5%	Pts with SIBO received ciprofloxacin 500 mg/d (n = 9), metronidazole 750 mg/d (n = 4), or rifaximin 1,200 mg/d (n = 2) for 1 mo, followed by probiotics containing <i>Lactobacillus casei</i> DG Tx ( $\geq 7,595$ billion living cells/100 g) for 2 mo	Normalization of GBT 1 mo after tx with probiotic, 86.7%
Boltin et al. <sup>58</sup> Prospective study	Israel Pts with bloating and flatulence (non-IBS)	LBT (15 g of lactulose/400 mL of water; BT result indicating an increase from baseline $>10$ ppm H <sub>2</sub> $\leq 90$ min)	41.5%	Rifaximin 1,200 mg/d for 10 d (n = 19)	Normalization of LBT, 42.1%
Chedid et al. <sup>59</sup> Retrospective, OL, SC	Pts with SIBO based on the positive LBT result	LBT (10 g of lactulose/30 mL of water; BT result at baseline $>10$ ppm for H <sub>2</sub> or $>7$ ppm for CH <sub>4</sub> if pts were compliant with tx, or an increase from baseline $\geq 20$ ppm H <sub>2</sub> or $\geq 12$ ppm CH <sub>4</sub> excretion $\leq 90$ min)	100%	Rifaximin 400 mg t.i.d. (n = 67) vs herbal therapy b.i.d. (n = 37; Dysbiocide and FC-Cidal [Biotics Research Laboratories, Rosenberg, TX] or Candibactin-AR and Candibactin-BR [Metagenics, Aliso Viejo, CA]) for 4 wk Rifaximin nonresponders (n = 41) received herbal therapy (n = 14) or triple antibiotic (clindamycin 300 mg t.i.d., metronidazole 250 mg t.i.d., and neomycin 500 mg t.i.d.; n = 10) for 4 wk	Negative LBT results with rifaximin (34%) vs herbal therapy (46%; P = 0.2) Herbal therapy vs rifaximin: OR, 1.8; CI, 0.8–4.4; P = 0.2 Retreatment of rifaximin nonresponders: Negative LBT results with herbal therapy (57.1%) vs antibiotics (60%; P > 0.99)
Fasano et al. <sup>30</sup> Prospective study	Italy Pts with Parkinson's disease (N = 33)	LBT or GBT (50 g of glucose/250 mL of water; BT result indicating an increase from baseline $>12$ ppm H <sub>2</sub> $\leq 120$ min)	54.5%	Rifaximin 400 mg t.i.d. for 7 d (n = 18)	77.8% of pts with SIBO had resolution of SIBO 1 mo after tx

Table 3. (continued)

Study and design	Location and population	Method used to diagnose SIBO	Pts with SIBO	Treatment	Efficacy
Moraru et al. <sup>60</sup> Prospective study	Romania Pts with IBS ( <i>N</i> = 72)	GBT (50 g of glucose/250 mL of water; BT result indicating an increase from baseline >20 ppm H <sub>2</sub> < 120 min)	11.1%	Rifaximin 400 mg t.i.d. for 14 d ( <i>n</i> = 8 with SIBO)	7 of 8 pts (87.5%) with SIBO underwent GBT and had resolution of SIBO and little to complete improvement (range, no improvement to complete improvement) of IBS symptoms 1 wk after the end of tx Of the 7 pts, 1 pt (14.2%) with SIBO received a second 2-wk course of rifaximin and had resolution of SIBO with repeat rifaximin tx
Rosania et al. <sup>61</sup> R	Italy Pts with SIBO ( <i>N</i> = 40)	LBT GBT (BT result [i.e., 2 H <sub>2</sub> peaks, with the first peak an increase from baseline of ≥10 ppm and a second, larger peak at ~60 min for both tests])	100%	Rifaximin 400 mg/d for 7 d, followed by probiotic ( <i>L. casei</i> DG 24 milliards/d) for 7 d, vs rifaximin 400 mg/d for 7 d, followed by prebiotic (fructooligosaccharides 2.5 g/d) for 7 d	Rifaximin/probiotic significantly improved symptoms from baseline to 6 mo: diffuse abdominal pain ( <i>P</i> < 0.001), left iliac area pain ( <i>P</i> < 0.002), abdominal distension ( <i>P</i> < 0.002), flatulence ( <i>P</i> < 0.001), and nausea ( <i>P</i> < 0.01) Rifaximin/prebiotic significantly improved symptoms from baseline to 6 mo: diffuse abdominal pain ( <i>P</i> < 0.02), left iliac area pain ( <i>P</i> < 0.005), abdominal distension ( <i>P</i> < 0.001), and flatulence ( <i>P</i> < 0.001)
Lauritano et al. <sup>62</sup> Prospective, PG, R	Italy Pts with GI symptoms ≥6 mo ( <i>N</i> = 142)	GBT (50 g of glucose; BT result indicating an increase from baseline >12 ppm H <sub>2</sub> ≤ 120 min)	NA	Rifaximin 400 mg t.i.d. ( <i>n</i> = 71) vs metronidazole 250 mg t.i.d. ( <i>n</i> = 71)	GBT normalization with rifaximin (63.4%) vs metronidazole (43.7%) 1 mo after tx Rifaximin vs metronidazole: OR, 1.5; 95% CI, 1.1–4.4; <i>P</i> < 0.05
Lauritano et al. <sup>28</sup> Prospective study	Italy Pts with overt hypothyroidism ( <i>n</i> = 50) vs healthy individuals ( <i>n</i> = 40)	GBT (50 g of glucose; BT result indicating an increase from baseline >12 ppm H <sub>2</sub> ≤ 120 min)	54% (pts) 5% (healthy individuals)	Rifaximin 400 mg t.i.d. for 7 d Only pts with positive GBT received rifaximin ( <i>n</i> = 27)	70.4% of pts with SIBO had eradication of SIBO 1 mo after the end of tx Abdominal discomfort, bloating, and flatulence significantly improved after 1 mo ( <i>P</i> < 0.01)
Majewski and McCallum <sup>15</sup> Study design not described	United States Pts with IBS ( <i>N</i> = 204)	GBT (50 g of glucose/150 mL of water; BT result indicating [1] for baseline measurement <10 ppm, then >20 ppm H <sub>2</sub> or CH <sub>4</sub> , or [2] for baseline measurement >10 ppm, then an increase from baseline >12 ppm H <sub>2</sub> or CH <sub>4</sub> ≤ 90 min)	46%	Rifaximin 200 mg q.i.d. for 4 wk Pts with positive GBT received rifaximin ( <i>n</i> = 8 of 204)	GBT results after rifaximin tx ( <i>n</i> = 8): 75% of pts had normal GBT and 12.5% of pts had normal GBT by hydrogen, not methane Overall symptom score improved in 87.5% of pts



Table 3. (continued)

Study and design	Location and population	Method used to diagnose SIBO	Pts with SIBO	Treatment	Efficacy
Scarpellini et al. <sup>63</sup> Prospective, PG, R	Italy Pts with positive GBT results, including pts with IBS (N = 80)	GBT (50 g of glucose/200 mL of water; BT result indicating an increase from baseline >12 ppm H <sub>2</sub> and/or >100% CH <sub>4</sub> ≤ 120 min)	100% IBS: 79%	Rifaximin 1,200 mg/d or 1,600 mg/d for 7 d	GBT normalization 1 mo after the end of tx: rifaximin 1,600 mg/d (80%) vs 1,200 mg/d (58%; P < 0.05; OR, 1.8; 95% CI, 1.1–8.0)
Lauritano et al. <sup>64</sup> Prospective, PG, R	Italy Pts with positive GBT results (N = 90)	GBT (50 g of glucose; BT result indicating an increase from baseline >12 ppm H <sub>2</sub> ≤ 120 min)	100%	Rifaximin 600 mg/d, 800 mg/d, or 1,200 mg/d for 7 d	GBT normalization 1 mo after the end of tx: rifaximin 600 mg/d (16.7%), 800 mg/d (26.7%), and 1,200 mg/d (60%) Rifaximin 1,200 mg/d vs 600 mg/d: OR, 7.5; 95% CI, 2.2–25.1; P < 0.001; rifaximin 1,200 mg/d vs 800 mg/d: OR, 4.1; 95% CI, 1.4–12.3; P < 0.01; and rifaximin 600 mg/d vs 800 mg/d: OR, 1.8; 95% CI, 0.5–6.4; P = NS
Di Stefano et al. <sup>65</sup> DB, R, C	Italy Pts with SIBO (N = 26)	GBT <sup>a</sup> (50 g of glucose; BT result indicating an increase from baseline >12 ppm H <sub>2</sub> ≤ 120 min; or in the fasted state, increase from baseline >12 ppm H <sub>2</sub> )	100%	Rifaximin 400 mg t.i.d. (n = 10) vs chlortetracycline 333 mg t.i.d. (n = 11) for 7 d	Rifaximin, but not chlortetracycline, significantly improved fasting, peak, and total hydrogen excretion from baseline (P < 0.03, P < 0.01, and P < 0.05, respectively)
Corazza et al. <sup>66</sup> Prospective study	Italy Pts with SIBO (N = 12)	LBT (10 g of 50% lactulose solution; BT result indicating an increase from baseline >10 ppm H <sub>2</sub> , ≥20 min before the colonic peak. Samples collected for 180 min)	100%	Rifaximin 400 mg b.i.d. or t.i.d. for 5 d (n = 6 in each group)	66.7% of pts in each group with eradication of SIBO 1 d after the end of tx Symptoms (i.e., abdominal distension, abdominal pain, and no. of bowel movements) improved from baseline in 83.3% of pts

<sup>a</sup>SIBO could also be diagnosed if any of the following were present: malabsorption or other predisposing conditions (i.e., autoimmune atrophic gastritis, chronic nonspecific diarrhea after travel to the tropical region, diabetic neuropathy, ileocolonic anastomosis, jejunoleal bypass, radiation enteritis, small bowel diverticula, small bowel obstruction, subtotal gastrectomy with gastrojejunostomy, and systemic sclerosis) (65).

b.i.d., twice a day; BT, breath test; C, controlled; CD, Crohn's disease; cfu, colony-forming unit; DB, double blind; GBT, glucose breath test; GERD, gastroesophageal reflux disease; GI, gastrointestinal; IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant IBS; IBS-M, mixed IBS; LBT, lactulose breath test; NA, not applicable; NS, not specified; OL, open label; OR, odds ratio; PG, parallel group; pt(s), patient(s); q.i.d., 4 times a day; R, randomized; SC, single center; SIBO, small intestinal bacterial overgrowth; t.i.d., 3 times a day; tx, treatment.

testing continued the diet for an additional 7 days (80). The cumulative symptomatic response rate for an elemental diet was 85% (79/93 patients) (80). A total of 14 patients (12%) were unable to tolerate the diet (80). At 1-month follow-up (n = 63 patients), 28/36 patients with improved IBS symptoms had a normalized breath test result (80). However, these diets are generally not palatable and difficult to adhere to and require a motivated patient (79).

A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols has been shown to be beneficial in IBS (81). This may be due to decreasing the exposure of small intestinal bacteria exposure to carbohydrate and its fermentation

products, thereby stifling bacterial growth or altering luminal fluid transport and/or colonic gas production. However, there is a lack of sound data to suggest that a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyol diet is beneficial for patients with SIBO.

### Recurrent SIBO

Approximately 44% of patients with SIBO may experience a relapse of symptoms within 9 months of initial treatment (82). For these patients, the most effective way to achieve eradication is by first identifying the appropriate organism(s) and providing targeted antibiotic therapy (i.e., “the right drug for the right bug”

**Table 4.** Summary of clinical studies of systemic antibiotics or probiotics

Study and design	Location and population	Method used to diagnose SIBO	Pts with SIBO	Treatment	Efficacy for eradication of SIBO	AEs
Ghoshal et al. <sup>43</sup> Prospective, DB, R, PBO-C, SC	India Pts with IBS ( <i>N</i> = 80)	Bacterial culture ( $\geq 10^5$ cfu/mL) and GBT (100 g of glucose/200 mL of water; BT result indicating an increase from baseline >12 ppm H <sub>2</sub> )	19%	Norfloxacin 400 mg b.i.d. vs PBO for 10 d Pts with SIBO: Norfloxacin ( <i>n</i> = 8) vs PBO ( <i>n</i> = 7) Pts without SIBO: Norfloxacin ( <i>n</i> = 32) vs PBO ( <i>n</i> = 33)	Norfloxacin eliminated SIBO in 100% of 4 pts who had a repeat test for SIBO 1 mo after tx	Tx well tolerated
Khalighi et al. <sup>69</sup> Prospective, R, DB, SC	Iran Pts with SIBO ( <i>N</i> = 30)	BT (BT result indicating an increase from baseline >20 ppm H <sub>2</sub> )	100%	Broad-spectrum antibiotics for 3 wk, then minocycline 100 mg b.i.d. for 15 d, followed by probiotic ( <i>Bacillus coagulans</i> and fructooligosaccharides) b.i.d. for 15 d ( <i>n</i> = 15) vs minocycline 100 mg b.i.d. for 15 d ( <i>n</i> = 15), then no tx for 6 mo	HBT results negative with antibiotic plus probiotic (93.3%) vs antibiotic (66.7%; <i>P</i> = 0.2)	NR
Sajjad et al. <sup>70</sup> C	United Kingdom Pts with NASH ( <i>n</i> = 12) vs healthy individuals ( <i>n</i> = 11)	GBT (75 g of glucose/250 mL of water; increase from baseline >20 ppm H <sub>2</sub> $\leq$ 120 min)	NR	Ciprofloxacin 500 mg b.i.d. for 5 d	GBT positive result at baseline and 4–7 d after tx: NASH: 50% vs 8.3%, respectively ( <i>P</i> = 0.025); healthy individuals: 9.1% vs 9.1%	NR
Castiglione et al. <sup>71</sup> R	Italy Pts with CD ( <i>N</i> = 145)	LBT (10 g of lactulose/100 mL of water; peak >20 ppm occurring 15 min before the colonic peak $\leq$ 180 min); or in the fasted state, H <sub>2</sub> and/or CH <sub>4</sub> > 12–15 ppm; If positive LBT, then GBT (50 g of glucose/100 mL of water; increase from baseline >12 ppm H <sub>2</sub> $\leq$ 120 min)	20%	Metronidazole 250 mg t.i.d. or ciprofloxacin 500 mg b.i.d. for 10 d	GBT normalization 1 wk after the end of tx: metronidazole (86.7%) vs ciprofloxacin (100%; <i>P</i> = NS)	Tx well tolerated; 1 pt receiving metronidazole discontinued due to nausea
Madrid et al. <sup>72</sup> R, PBO-C	Chile Pts with liver cirrhosis ( <i>N</i> = 34)	LBT (12 g of lactulose/300 mL of water; baseline >20 ppm H <sub>2</sub> and $\geq$ 100 ppm H <sub>2</sub> $\leq$ 60 min)	—	Norfloxacin 400 mg b.i.d. and neomycin 500 mg t.i.d. for alternating 15-d periods ( <i>n</i> = 12), cisapride 10 mg t.i.d. ( <i>n</i> = 12), or PBO t.i.d. ( <i>n</i> = 10) for 6 mo	Patients positive for SIBO in norfloxacin and neomycin, cisapride, and PBO groups: baseline: 67%, 42%, and 40%, respectively; 3 mo: 50%, 25%, and 60%; 6 mo: 17%, 8%, and 60%	NR

Table 4. (continued)

Study and design	Location and population	Method used to diagnose SIBO	Pts with SIBO	Treatment	Efficacy for eradication of SIBO	AEs
Attar et al. <sup>73</sup> R, DB, CO	France Pts with chronic diarrhea (i.e., >3 stools/d for >3 mo), predisposition to SIBO, and positive GBT result (N = 20)	GBT (50 g of glucose; increase from baseline >10 ppm H <sub>2</sub> < 120 min)	—	Norfloxacin 800 mg/d, amoxicillin-clavulanic acid 1,500 mg/d, <i>S. boulardii</i> 1,500 mg/d, or PBO for 7 d	GBT normalized in 30% and 50% of 10 pts receiving norfloxacin and amoxicillin-clavulanic acid, respectively, at the end of tx; no change from baseline with PBO and <i>S. boulardii</i>	NR
Probiotics						
Yao et al. <sup>89</sup> DB, R, PBO-C, OL	Australia Pts with IBS (N = 56)	LBT (15 g of lactulose/100 mL of solution, including 100 mg of <sup>13</sup> C sodium acetate tracer; increase ≥10 ppm H <sub>2</sub> at ≥2 consecutive time points <90 min)	100%	Probiotic (Yakult; contains 6.5 × 10 <sup>9</sup> cfu <i>L. casei</i> strain Shirota; n = 28) vs PBO (n = 28) for 6 wk, then OL probiotic for 6 wk (n = 45)	Loss of early rise in breath hydrogen after lactulose with probiotic (43%) vs PBO (54%) in the DB phase OL phase: probiotic (33%) vs DB PBO (33%)	DB phase: 37% vs 32% (e.g., UTI, URTI, gastroenteritis, musculoskeletal pain, sinusitis, anxiety, and depression) OL phase: 24%
Kwak et al. <sup>74</sup> R, PBO-C	South Korea Pts with chronic liver disease (N = 52; n = 50 completed study)	LBT (10 g of lactulose/250 mL of water; baseline ≥20 ppm H <sub>2</sub> or increase >20 ppm H <sub>2</sub> < 90 min)	26%	Probiotic (Duolac Gold; contains 5 × 10 <sup>9</sup> total viable cells: <i>Bifidobacterium bifidum</i> , <i>Bifidobacterium lactis</i> , <i>Bifidobacterium longum</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus acidophilus rhamnosus</i> , and <i>Streptococcus thermophilus</i> ; n = 25) vs PBO (n = 25) b.i.d. for 4 wk	Improvement in SIBO (by LBT) with probiotic (24%) vs PBO (0%; P < 0.05)	NR
Lunia et al. <sup>76</sup> OL, R	India Pts with cirrhosis and no previous history of HE (N = 160)	GBT (100 g of glucose/200 mL of water; increase from baseline >12 ppm H <sub>2</sub> < 180 min)	36.9%	Probiotic (VSL#3, Sigma-Tau Pharmaceuticals, Gaithersburg, MD; n = 86) vs PBO (n = 74) t.i.d.	Significant decrease from baseline in pts with SIBO (by GBT) receiving probiotic at 3 mo (38.4% vs 17.7%; P = 0.006), but not PBO (35.1% vs 33.9%; P = 0.9)	No AEs observed
Stotzer et al. <sup>75</sup> DB, CO	Sweden Pts with SIBO (N = 17; n = 14 completed study)	Achieve ≥2 criteria: Bacterial culture (>10 <sup>5</sup> cfu/mL) GBT (50 g of glucose/250 mL of water; increase from baseline >12 ppm H <sub>2</sub> < 120 min) Tx response (GBT and symptoms)	100%	Probiotic ( <i>Lactobacillus fermentum</i> KLD 1–3 × 10 <sup>11</sup> bacteria) vs PBO b.i.d. for 4 wk, followed by a 4-wk washout period, then cross-over to PBO or probiotic for 4 wk	No significant difference between probiotic and PBO regarding GBT, stool frequency, or symptom score	NR
AE, adverse event; b.i.d., twice a day; BT, breath test; C, controlled; CD, Crohn's disease; cfu, colony-forming unit; CO, cross-over; DB, double blind; GBT, glucose breath test; HBT, hydrogen breath test; HE, hepatic encephalopathy; IBS, irritable bowel syndrome; LBT, lactulose breath test; NASH, nonalcoholic steatohepatitis; NR, not reported; NS, not specified; OL, open label; PBO, placebo; PBO-C, placebo-controlled; pt(s), patient(s); R, randomized; SC, single center; SIBO, small intestinal bacterial overgrowth; t.i.d., 3 times a day; tx, treatment; URTI, upper respiratory tract infection; UTI, urinary tract infection.						

approach). This is best achieved by small bowel aspiration, culture, and sensitivity. Another strategy is to identify and correct any underlying condition(s), such as avoiding medications that delay gut transit, reduce PPI and opioid use, and improve glycemic control, and adhesiolysis or correction of blind loops (7,83). Prokinetic agents improve motility and could enhance antegrade clearance of bacteria (72). Hence, a trial of prokinetic agents such as cisapride, tegaserod, erythromycin, and prucalopride may be considered, but there are no data to support their use, and some of these agents are not universally available or have risks (72,84,85). Some factors are not reversible, such as radiation enteritis, systemic sclerosis, postgastric resection, and surgical resection of the ileocecal valve (83,86). In such patients, some experts recommend cyclical monthly low-dose antibiotic therapy using 2 or 3 antibiotics (83,86). However, these approaches merit controlled trials.

### Treatment failures

Approximately 30%–40% of patients may not have resolution of SIBO symptoms with antibiotic trials as shown in Table 4. In such cases, other overlapping or alternate diagnosis should be considered, such as disaccharide deficiency or food intolerances (87,88). For example, a patient with SIBO and lactose intolerance could present with symptoms of gas, bloating, and diarrhea; antibiotics will only confer partial resolution of symptoms. In addition, the patient will require a lactose-free diet. Therefore, a comprehensive assessment of symptoms with appropriate diagnostic tests and careful exclusion of other conditions is important in a patient with risk factors or in those with suboptimal response to therapy. Rigorous controlled studies are needed to guide clinical management. Moreover, other overlapping conditions such as pancreatic exocrine insufficiency, bile acid malabsorption, hormonal oversecretion, medications, functional bloating, hypersensitivity, and factitious symptoms should all be considered as possible causes.

### CONCLUSIONS

SIBO causes nonspecific GI symptoms and is associated with other GI and non-GI conditions. Because of the broad range of symptoms experienced by these patients, symptoms alone cannot be used to establish a SIBO diagnosis. Consequently, diagnostic testing is required. Although inconsistencies exist, bacterial culture of small bowel aspirates is generally accepted as the best diagnostic method for the diagnosis of SIBO, but aseptic precautions and proper technique is key. Although a perfect breath test for SIBO is currently lacking, the 2017 North American consensus document offers clinical direction regarding choice of substrate, testing methodology, and interpretation of results, which requires further refining as new evidence emerges (8). Breath testing is considered a safe and noninvasive diagnostic tool for SIBO, although gaps in knowledge regarding the optimal method(s) of performing and interpreting the breath test remain.

Therapies shown to be efficacious and well tolerated for patients with SIBO include the nonsystemic antibiotic rifaximin and systemic antibiotics. However, given the differences across study populations, diagnostic tests and interpretation, and dosing and duration of antibiotic therapy, large well-designed randomized clinical trials with appropriate patient selection and well-defined symptoms and objective criteria are warranted to guide effective management of SIBO.

### CONFLICTS OF INTEREST

**Guarantor of the article:** Satish S. C. Rao, MD, PhD, is the guarantor of the narrative review and assumes responsibility for the decision to publish.

**Specific author contributions:** S.S.C.R. and J.B. were involved in interpreting data included in this review, drafting the manuscript, and approving the final draft of the review.

**Financial support:** This work was supported by Salix Pharmaceuticals, Bridgewater, NJ. S.S.C.R.: Previously received research funding from Salix Pharmaceuticals.

**Potential competing interests:** None.

### ACKNOWLEDGEMENTS

Technical editorial assistance was provided, under the direction of the author, by Mary Beth Moncrief, PhD, and Sophie Bolick, PhD, Synchrony Medical Communications, LLC, West Chester, PA.

### REFERENCES

1. D'Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. *Clin Chim Acta* 2015;451:97–102.
2. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol* 2016;14:e1002533.
3. Stearns JC, Lynch MD, Senadheera DB, et al. Bacterial biogeography of the human digestive tract. *Sci Rep* 2011;1:170.
4. Drasar BS, Shiner M, McLeod GM. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. *Gastroenterology* 1969;56:71–9.
5. Gorbach SL. Population control in the small bowel. *Gut* 1967;8:530–2.
6. Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: Duodenal aspiration vs glucose breath test. *Neurogastroenterol Motil* 2015;27:481–9.
7. Jacobs C, Coss Adame E, Attaluri A, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. *Aliment Pharmacol Ther* 2013;37:1103–11.
8. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. *Am J Gastroenterol* 2017;112:775–84.
9. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. *Aliment Pharmacol Ther* 2011;33:1059–67.
10. Hoog CM, Lindberg G, Sjoqvist U. Findings in patients with chronic intestinal dysmotility investigated by capsule endoscopy. *BMC Gastroenterol* 2007;7:29.
11. Posserud I, Stotzer PO, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. *Gut* 2007;56:802–8.
12. Ghoshal UC, Srivastava D, Ghoshal U, et al. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. *Eur J Gastroenterol Hepatol* 2014;26:753–60.
13. Pylaris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: Relationship with irritable bowel syndrome. *Dig Dis Sci* 2012;57:1321–9.
14. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. *Am J Gastroenterol* 2000;95:3503–6.
15. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trial. *Adv Med Sci* 2007;52:139–42.
16. Fialho A, Fialho A, Kochhar G, et al. Association between small intestinal bacterial overgrowth by glucose breath test and coronary artery disease. *Dig Dis Sci* 2017;63:412–21.
17. Rao SSC, Tan G, Abdulla H, et al. Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)? *Clin Transl Gastroenterol* 2018;9:146.
18. Franco DL, Disbrow MB, Kahn A, et al. Duodenal aspirates for small intestine bacterial overgrowth: Yield, PPIs, and outcomes after treatment at a tertiary academic medical center. *Gastroenterol Res Pract* 2015;2015:971582.

19. Lombardo L, Foti M, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. *Clin Gastroenterol Hepatol* 2010;8:504–8.
20. Ratuapli SK, Ellington TG, O'Neill MT, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. *Am J Gastroenterol* 2012;107:730–5.
21. Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. *Clin Transl Gastroenterol* 2015;6:e89.
22. Su T, Lai S, Lee A, et al. Meta-analysis: Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. *J Gastroenterol* 2018;53:27–36.
23. Rao SSC, Rehman A, Yu S, et al. Brain foginess, gas and bloating: A link between SIBO, probiotics and metabolic acidosis. *Clin Transl Gastroenterol* 2018;9:162.
24. Costa MB, Azeredo IL Jr, Marciano RD, et al. Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test. *Arq Gastroenterol* 2012;49:279–83. Portuguese.
25. Greco A, Caviglia GP, Brignolo P, et al. Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. *Scand J Gastroenterol* 2015;50:1376–81.
26. Kim DB, Paik CN, Kim YJ, et al. Positive glucose breath tests in patients with hysterectomy, gastrectomy, and cholecystectomy. *Gut Liver* 2017;11:237–42.
27. Virally-Monod M, Tielmans D, Kevorkian JP, et al. Chronic diarrhoea and diabetes mellitus: Prevalence of small intestinal bacterial overgrowth. *Diabetes Metab* 1998;24:530–6.
28. Lauritano EC, Bilotta AL, Gabrielli M, et al. Association between hypothyroidism and small intestinal bacterial overgrowth. *J Clin Endocrinol Metab* 2007;92:4180–4.
29. Therrien A, Bouchard S, Sidani S, et al. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: A case-control study. *Can J Gastroenterol Hepatol* 2016;2016:7424831.
30. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. *Mov Disord* 2013;28:1241–9.
31. Weinstock LB, Walters AS. Restless legs syndrome is associated with irritable bowel syndrome and small intestinal bacterial overgrowth. *Sleep Med* 2011;12:610–3.
32. Egeberg A, Weinstock LB, Thyssen EP, et al. Rosacea and gastrointestinal disorders: A population-based cohort study. *Br J Dermatol* 2017;176:100–6.
33. Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: Clinical effectiveness of its eradication. *Am J Gastroenterol* 2008;103:1257–62.
34. Sabaté JM, Jouët P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. *Obes Surg* 2008;18:371–7.
35. Zhang Y, Liu G, Duan Y, et al. Prevalence of small intestinal bacterial overgrowth in multiple sclerosis: A case-control study from China. *J Neuroimmunol* 2016;301:83–7.
36. Wang L, Yu YM, Zhang YQ, et al. Hydrogen breath test to detect small intestinal bacterial overgrowth: A prevalence case-control study in autism. *Eur Child Adolesc Psychiatry* 2018;27:233–40.
37. Lasa JS, Zubiaurre I, Fanjul I, et al. Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients. *Rev Gastroenterol Mex* 2015; 80:171–4.
38. Rana SV, Sinha SK, Lal S, et al. Small intestinal bacterial overgrowth in North Indian patients with celiac disease. *Trop Gastroenterol* 2007;28: 159–61.
39. Rubio-Tapia A, Barton SH, Rosenblatt JE, et al. Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. *J Clin Gastroenterol* 2009;43:157–61.
40. Niu XL, Liu L, Song ZX, et al. Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson's disease. *J Neural Transm (Vienna)* 2016;123:1381–6.
41. Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. *Mov Disord* 2011;26:889–92.
42. Ghoshal UC, Ghoshal U. Small intestinal bacterial overgrowth and other intestinal disorders. *Gastroenterol Clin North Am* 2017;46:103–20.
43. Ghoshal UC, Srivastava D, Misra A, et al. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: A randomized, double-blind, placebo-controlled trial. *Eur J Gastroenterol Hepatol* 2016; 28:281–9.
44. Erdogan A, Rao SS. Small intestinal fungal overgrowth. *Curr Gastroenterol Rep* 2015;17:16.
45. Levitt MD, Bond JH Jr. Volume, composition, and source of intestinal gas. *Gastroenterology* 1970;59:921–9.
46. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: An evidence-based review of indications and pitfalls in interpretation. *Am J Gastroenterol* 2002;97:1113–26.
47. Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: The Rome Consensus Conference. *Aliment Pharmacol Ther* 2009;29(Suppl 1): 1–49.
48. Keller J, Franke A, Storr M, et al. Clinically relevant breath tests in gastroenterological diagnostics: Recommendations of the German Society for Neurogastroenterology and Motility as well as the German Society for Digestive and Metabolic Diseases. *Z Gastroenterol* 2005;43: 1071–90. German.
49. Erdogan A, Lee YY, Badger C, et al. What is the optimal threshold for an increase in hydrogen and methane levels with glucose breath test (GBT) for detection of small intestinal bacterial overgrowth (SIBO)? *Gastroenterology* 2014;146:S–532.
50. Ghoshal UC. How to interpret hydrogen breath tests. *J Neurogastroenterol Motil* 2011;17:312–7.
51. Lin EC, Massey BT. Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth. *Clin Gastroenterol Hepatol* 2016;14:203–8.
52. Saad RJ, Chey WD. Breath testing for small intestinal bacterial overgrowth: Maximizing test accuracy. *Clin Gastroenterol Hepatol* 2014; 12:1964–72, quiz e1119–1920.
53. Viswanathan L, Larion S, Shaffer N, et al. Endoscopically assisted glucose breath test (EAGBT): A novel diagnostic approach for distal sibo. *Gastroenterol* 2017;152:S413.
54. Kalantar-Zadeh K, Berean KJ, Ha N, et al. A human pilot trial of ingestible electronic capsules capable of sensing different gases in the gut. *Nat Electronics* 2018;1:79–87.
55. Singh S, Allan N, Wahl C, et al. Development of a swallowable diagnostic capsule to monitor gastrointestinal health. Paper presented at: AGA 2019. *Gastroenterology* 2019;156(Suppl 1):s-376.
56. Shah SC, Day LW, Somsouk M, et al. Meta-analysis: Antibiotic therapy for small intestinal bacterial overgrowth. *Aliment Pharmacol Ther* 2013;38: 925–34.
57. Bae S, Lee KJ, Kim YS, et al. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects. *J Korean Med Sci* 2015;30:757–62.
58. Boltin D, Perets TT, Shporn E, et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. *Ann Clin Microbiol Antimicrob* 2014;13:49.
59. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. *Glob Adv Health Med* 2014;3:16–24.
60. Moraru IG, Portincasa P, Moraru AG, et al. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin: A pilot study. *Rom J Intern Med* 2013;51:143–7.
61. Rosania R, Giorgio F, Principi M, et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: A comparative evaluation. *Curr Clin Pharmacol* 2013;8: 169–72.
62. Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: Rifaximin versus metronidazole. *Eur Rev Med Pharmacol Sci* 2009;13:111–6.
63. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. *Aliment Pharmacol Ther* 2007;25:781–6.
64. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. *Aliment Pharmacol Ther* 2005;22:31–5.
65. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. *Aliment Pharmacol Ther* 2000;14:551–6.
66. Corazza GR, Ventrucci M, Stocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. *J Int Med Res* 1988;16:312–6.
67. Gatta L, Scarpignato C. Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. *Aliment Pharmacol Ther* 2017;45:604–16.

68. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. *Aliment Pharmacol Ther* 2012; 36:1084–93.
69. Khalighi AR, Khalighi MR, Behdani R, et al. Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)—A pilot study. *Indian J Med Res* 2014;140:604–8.
70. Sajjad A, Mottershead M, Syn WK, et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2005;22:291–9.
71. Castiglione F, Rispo A, Di Girolamo E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. *Aliment Pharmacol Ther* 2003;18:1107–12.
72. Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cisapride and antibiotics in liver cirrhosis: Effect on small intestinal motility, bacterial overgrowth, and liver function. *Am J Gastroenterol* 2001;96:1251–5.
73. Attar A, Flourié B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: A crossover, randomized trial. *Gastroenterology* 1999;117:794–7.
74. Kwak DS, Jun DW, Seo JG, et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. *Eur J Gastroenterol Hepatol* 2014; 26:1353–9.
75. Stotzer PO, Blomberg L, Conway PL, et al. Probiotic treatment of small intestinal bacterial overgrowth by *Lactobacillus fermentum* KLD. *Scand J Infect Dis* 1996;28:615–9.
76. Lunia MK, Sharma BC, Sharma P, et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: A randomized controlled trial. *Clin Gastroenterol Hepatol* 2014;12:1003–8.e1001.
77. Zhong C, Qu C, Wang B, et al. Probiotics for preventing and treating small intestinal bacterial overgrowth: A meta-analysis and systematic review of current evidence. *J Clin Gastroenterol* 2017;51:300–11.
78. Quigley EMM, Pot B, Sanders ME. “Brain fogginess” and D-lactic acidosis: Probiotics are not the cause. *Clin Transl Gastroenterol* 2018;9:187.
79. Winitz M, Adams RF, Seedman DA, et al. Studies in metabolic nutrition employing chemically defined diets. II. Effects on gut microflora populations. *Am J Clin Nutr* 1970;23:546–59.
80. Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. *Dig Dis Sci* 2004; 49:73–7.
81. Dionne J, Ford AC, Yuan Y, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. *Am J Gastroenterol* 2018; 113:1290–300.
82. Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. *Am J Gastroenterol* 2008; 103:2031–5.
83. Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: Pathogenesis and clinical significance. *Ther Adv Chronic Dis* 2013;4: 223–31.
84. Hennessy S, Leonard CE, Newcomb C, et al. Cisapride and ventricular arrhythmia. *Br J Clin Pharmacol* 2008;66:375–85.
85. Pimentel M, Morales W, Lezcano S, et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. *Gastroenterol Hepatol (N Y)* 2009;5:435–42.
86. Pittman N, Rawn SM, Wang M, et al. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: A systematic review. *Rheumatology (Oxford)* 2018;57:1802–11.
87. Viswanathan L, Larion S, Shaffer N, et al. How useful is histological testing of disaccharidase deficiency in the evaluation of unexplained GI symptoms in adults? *AGA Abstracts* 2017;152:S7–S8.
88. Philpott H, Yu S, Rao S. Letter to the editor: It's all in the mix: Diagnosis and management of food intolerance. *Clin Gastro Hepatol* 2016;14: 1221–4.
89. Yao CK, Barrett JS, Philpott H, et al. Poor predictive value of breath hydrogen response for probiotic effects in IBS. *J Gastroenterol Hepatol* 2015;30:1731–9.

---

**Open Access** This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.